![]() Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. PDCO has lost 1.8% compared with the industry’s 10.5% fall. Patterson Companies has outperformed its industry in the past year. The company’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%. Patterson Companies has an estimated long-term growth rate of 9.6%. MRK has gained 19.6% against the industry’s 15.7% growth. Merck has outperformed its industry in the past year. The company surpassed earnings estimates in the trailing three quarters and missed in one, delivering a surprise of 13.4%, on average. Merck has a long-term earnings growth rate of 10.1%. AMN has gained 13.9% against the industry’s 32.7% fall. You can see the complete list of today’s Zacks #1 Rank stocks here.ĪMN Healthcare has outperformed its industry in the past year. It currently flaunts a Zacks Rank #1 (Strong Buy). The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 15.6%, on average. PDCO.ĪMN Healthcare has a long-term earnings growth rate of 1.1%. Zacks Rank and Key PicksĬurrently, Quest Diagnostics carries a Zacks Rank #2 (Buy).Ī few better-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. The stock has gained 0.1% against a 38.6% decline of the industry. Share Price PerformanceĭGX has outperformed its industry in the past year. The company is bridging healthcare gaps to address health disparities in underserved communities, including those affected by COVID-19, through its Quest for Health Equity (Q4HE) initiative. ![]() The service allows individuals to use Abbott’s BinaxNOW COVID-19 Ag Card Home Test under the supervision of a certified telehealth proctor. The new service features proctored telehealth visits in partnership with eMed. In January 2022, the company announced the availability of an at-home COVID-19 rapid antigen test service for consumer purchase through its consumer-initiated testing platform, QuestDirect. Uninsured and insured individuals aged 2 years and older are eligible for the program. To qualify, individuals must complete a brief online screening questionnaire through the company’s consumer-initiated testing service, QuestDirect. Under the ICATT program, Quest Diagnostics will enhance access to $0 out-of-pocket COVID-19 testing to qualifying uninsured individuals at roughly 1,200 of its 2,100 patient service centers. The CDC-brokered model may help curb the spread of SARS-CoV-2 and other contagions by making high-quality laboratory testing financially accessible. Quest Diagnostics’ management is optimistic about CDC’s efforts to increase accessibility to critical COVID-19 laboratory testing for individuals in most need through public-private collaboration. This collaboration will enable Quest Diagnostics to expand access to COVID-19 diagnostic services in underserved communities to bridge the equity gaps in the country’s pandemic response. ![]() However, financial terms regarding the same have been kept in wraps. The ICATT program aims to support free COVID-19 laboratory testing for patients across communities impacted by the pandemic in the United States.įollowing a competitive bid, the CDC selected Quest Diagnostics as a participating partner in the ICATT program. Quest Diagnostics Incorporated DGX recently joined as a participating partner in the Centers for Disease Control and Prevention's (CDC) Increasing Community Access to Testing (ICATT) for the COVID-19 program.
0 Comments
Leave a Reply. |